DoctorDirectory.ai
Menu

Patient guide · Obesity and weight

Obesity and weight: what good care looks like

Obesity is a chronic disease with effective treatments, including FDA-approved GLP-1 medicines. Here is what guideline-based care includes and why compounded versions are a red flag.

Medically reviewed by Dr. Mohammed Alo, DO, FACCGuideline version AACE/ACE Obesity Guideline + current society guidance on anti-obesity medications

What obesity is, in plain language

Obesity is a chronic disease in which the body stores excess fat in a way that raises the risk of other health problems, including type 2 diabetes, high blood pressure, heart disease, sleep apnea, and certain cancers. It is usually screened for with body mass index (BMI), a ratio of weight to height, though BMI is an imperfect measure and does not directly measure body fat or health.

Obesity results from a mix of genetics, hormones, environment, and behavior, not simply a lack of willpower, which is why current guidelines treat it as a medical condition requiring the same evidence-based approach as any other chronic disease.

What the current guidelines recommend

The main guideline is the AACE/ACE Clinical Practice Guidelines for Obesity, alongside current society guidance on anti-obesity medications, which frame obesity as a chronic disease requiring long-term management, not a short-term diet. Treatment intensity is matched to your degree of risk and the health complications you already have, and effective medicines are recommended as part of, not instead of, lifestyle treatment.

The treatments, and why each one is recommended

Lifestyle treatment (a structured eating plan, increased physical activity, and behavioral support) is the foundation for everyone and produces meaningful health benefits even with modest weight loss.

GLP-1 and GLP-1/GIP receptor agonists (semaglutide, tirzepatide) are the most effective medicines currently available, producing average weight loss in the range of 15 to 20 percent of body weight in trials, by reducing appetite and slowing digestion. Semaglutide has also been shown, in the SELECT trial, to reduce heart attacks, strokes, and cardiovascular death in people with obesity and existing heart disease, independent of the weight lost.

Older anti-obesity medicines (phentermine-topiramate, naltrexone-bupropion) remain options, particularly when GLP-1 medicines are not accessible or not tolerated, though they produce more modest weight loss.

Bariatric surgery is the most effective treatment for severe obesity or obesity with serious complications, and is recommended for appropriate candidates based on BMI and health status.

Compounded semaglutide or tirzepatide, sold outside the FDA-approved supply chain, is not recommended: it is not verified for purity, dose accuracy, or safety.

What guideline-based care looks like at a visit

A good clinician takes a full history of your weight, prior attempts, and related health conditions, checks labs relevant to obesity-related complications (blood sugar, cholesterol, liver enzymes), and sets a plan that combines lifestyle support with medicine or referral when appropriate. Follow-up should track weight trend, side effects, and improvement in related conditions like blood pressure or blood sugar, not weight loss alone, and should never promise a specific number of pounds by a specific date.

Red flags that a clinician is not following the guidelines

  • Compounded semaglutide or tirzepatide instead of FDA-approved products
  • Peptides, injections, or supplements sold in the office
  • No monitoring plan, no nutrition or activity plan
  • Promises of a specific number of pounds in a specific time

Why choosing a guideline-based clinician matters

In the SELECT trial, semaglutide reduced major cardiovascular events by 20 percent in people with obesity and known heart disease, even though this is a drug most people think of only for weight loss. Even a 5 to 10 percent reduction in body weight meaningfully improves blood pressure, blood sugar, and cholesterol, which is why guideline-based treatment focuses on sustained health improvement rather than rapid weight loss alone.

Questions to ask your doctor

  1. Which guideline do you follow for obesity, and what year is it from?
  2. Which of the recommended treatments am I on, and if not, why not?
  3. What targets are we aiming for, and how will we track them?
  4. What should make me call you before my next visit?
  5. Do you sell any supplements or compounded medicines? (A guideline-based clinic does not.)

Find a vetted weight loss doctor near you

Every weight loss doctor on DoctorDirectory.ai is license-verified, board-certified, and has signed a dated attestation to these guidelines. No patient reviews or star ratings, just facts you can check.

The guidelines behind this guide

Summaries in plain language, with links to the official documents and PDFs.

  • American Gastroenterological Association · 2022

    AGA Clinical Practice Guideline on Pharmacological Interventions for Adults With Obesity

    • Reviews the trial evidence for each FDA-approved weight-loss medicine and recommends them, with lifestyle care, for adults with obesity.
    • Semaglutide and other GLP-1-based medicines showed the largest weight loss; phentermine-topiramate, naltrexone-bupropion, and others are also supported.
    • Recommends against orlistat for most patients because of small benefit and side effects.
    Read the guidelinedoi:10.1053/j.gastro.2022.08.045
  • Endocrine Society · 2015

    Pharmacological Management of Obesity: An Endocrine Society Clinical Practice Guideline

    • Anti-obesity medicines are appropriate for people with BMI 30 or more, or 27 or more with a weight-related condition, alongside lifestyle care.
    • Only FDA-approved medicines should be used, and a medicine that has not produced 5 percent weight loss by 12 weeks should be stopped or changed.
    • Explains which common medicines for other conditions cause weight gain and what to switch to.
    Read the guidelinedoi:10.1210/jc.2014-3415
  • AHA / ACC / The Obesity Society · 2013

    2013 AHA/ACC/TOS Guideline for the Management of Overweight and Obesity in Adults

    • Losing 5 to 10 percent of body weight meaningfully improves blood pressure, cholesterol, and blood sugar.
    • A structured lifestyle program (diet, activity, behavior support) for at least 6 months is the foundation.
    • Bariatric surgery is an option for BMI 40 or more, or 35 or more with a weight-related condition.
    Read the guidelineDownload PDFdoi:10.1161/01.cir.0000437739.71477.ee

All source guidelines

Find a vetted weight loss doctor near you

Every weight loss doctor listed has a verified license, board certifications on record, and a dated attestation to these guidelines. No reviews, no ratings.

Cardiologist, Preventive cardiologist · Toledo, OH

Board-certified cardiologist and internist in northwest Ohio who focuses on preventive cardiology, weight loss and lipidology, and is an Assistant Clinical Professor of Medicine at Ohio University.

Call (419) 567-1999
License verifiedBoard-certified: Cardiology, Internal medicineAttested Oct 1, 2026Screened Sep 20, 2026No supplement, peptide, or compounded drug salesAccepting new patients

VerifiedTelehealth

Weight loss doctor, Menopause specialist · Warren, MI

Family physician board-certified in family, obesity, and lifestyle medicine who founded the Michigan Longevity Clinic in Warren, Michigan, focusing on medical weight loss and metabolic health, and works as a hospitalist at ProMedica Monroe.

Call (586) 302-3067
License verifiedBoard-certified: Obesity medicine, Family medicineAttested Oct 1, 2026Screened Sep 20, 2026No supplement, peptide, or compounded drug salesAccepting new patients

Weight loss doctor, Internal medicine doctor · Arlington, TX

Dr. Mohammed Imam is a board-certified allergist and immunologist who treats both children and adults in Arlington, Texas. He completed his medical training in osteopathic medicine, internal medicine, and an allergy/immunology fellowship before founding his own clinic.

Call (817) 678-5575
License verifiedBoard-certified: Obesity medicine, Internal medicine, PediatricsAttested Oct 1, 2026Screened Sep 21, 2026No supplement, peptide, or compounded drug salesAccepting new patients

This guide explains what the published guidelines recommend in plain language. It is educational, not medical advice, and it does not replace a visit with your own clinician. Guidelines change; check the review date above.

Something out of date? Tell us. Read our editorial policy.